Article citationsMore>>

Prevoo, M.L.L., Van’T Hof, M.A., Kuper, H.H., Van Leeuwen, M.A., Van De Putte, L.B.A. and Van Riel, P.L.C.M. (1995) Modified Disease Activity Scores That Include Twenty-Eight-Joint Counts Development and Validation in a Prospective Longitudinal Study of Patients with Rheumatoid Arthritis. Arthritis & Rheumatism, 38, 44-48.
https://doi.org/10.1002/art.1780380107

has been cited by the following article:

• TITLE: Rituximab Induced Vasculitis: Dose the Antigen-Antibody Complex of Rituximab Play a Role in Developing Leukocytoclastic Vasculitis?—A Case Report and Review of the Literature

  AUTHORS: Ahmed A. AlTaroti, Zahra Z. AlZahir, Salah Abohelaika

  KEYWORDS: Rheumatoid Arthritis, Rituximab, Vasculitis, Leukocytoclastic Vasculitis

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.9, September 11, 2024

  ABSTRACT: Rituximab is a monoclonal antibody that targets CD20, which is a specific B-cell surface antigen. It was the first monoclonal antibody that was approved for the treatment of non-Hodgkin lymphoma, rheumatoid arthritis, and other cutaneous lymphoid malignancies. There are many off-label uses of rituximab, such as systemic lupus erythematosus, autoimmune hemolytic anemia, multiple sclerosis, graft-versus-host disease, chronic lymphocytic leukemia, and chronic immune-mediated thrombocytopenia. Among the rare side effects associated with rituximab treatment is vasculitis, more specifically, leukocytoclastic vasculitis. Here, we describe a 21-year-old Saudi female with leukocytoclastic vasculitis occurring three months after treatment with rituximab.